Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Deferred Revenue: 2019-2022

Historic Current Deferred Revenue for Fulcrum Therapeutics (FULC) over the last 4 years, with Dec 2022 value amounting to $934,000.

  • Fulcrum Therapeutics' Current Deferred Revenue rose 50.00% to $600,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $600,000, marking a year-over-year increase of 50.00%. This contributed to the annual value of $934,000 for FY2022, which is 80.17% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Current Deferred Revenue of $934,000 as of FY2022, which was down 80.17% from $4.7 million recorded in FY2021.
  • Over the past 5 years, Fulcrum Therapeutics' Current Deferred Revenue peaked at $14.9 million during FY2020, and registered a low of $934,000 during FY2022.
  • Its 3-year average for Current Deferred Revenue is $6.9 million, with a median of $4.7 million in 2021.
  • In the last 5 years, Fulcrum Therapeutics' Current Deferred Revenue surged by 273.78% in 2020 and then crashed by 80.17% in 2022.
  • Yearly analysis of 4 years shows Fulcrum Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then surged by 273.78% to $14.9 million in 2020, then crashed by 68.40% to $4.7 million in 2021, then plummeted by 80.17% to $934,000 in 2022.